Morten Mau-Sørensen
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients (NCT05170256) | Morten Mau-Sørensen | 2022-02-04 |
Track Morten Mau-Sørensen automatically
Every clearance here is in the API, with alerts when new ones post.